Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
This commentary examines the consequences of a medical student’s dishonesty during clinical rounds when she lacked the lab results the attending physician asked her for.
Clinical trials for the blood substitute PolyHeme exposed the possibility for ambiguous interpretation of the FDA’s waiver of informed consent for emergency research.
A first-person account of the development and implementation of a professionalism curriculum at New York University School of Medicine that uses online student portfolios as its principal means for evaluating professional development.
In “Ethics of International Research: What Does Responsiveness Mean?” Christine Grady explains how developing countries are vulnerable to exploitation by researchers and explores what “responsiveness” to the needs of those populations might entail.
A physicians urges practitioners to use cost-effective alternatives to dispensing samples to patients who cannot afford to pay for their prescriptions.
A physician explains that the sale of nonprescription cosmeceuticals from a dermatology office should be done in a manner that is educational but non-threatening to patients.
A physician and a lawyer argue against a dermatology clinic switching from a small, reliable pathology lab to a large-scale pathology lab in order to receive volume discounts and increase profit.